This will be a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of PLS240 in eligible participants with ESKD and SHPT.
To evaluate the efficacy and safety of Botulinum Toxin Type A PUrified Neurotoxin Complex (BOTOX) compared to placebo for the treatment of upper limb essential tremor.
After completing enrollment in the original DEFENDO Study, patients will be invited to enter the DEFENDO Long-Term Follow-up Study (all standard of care is permitted). Two additional long-term follow-up visits will occur at 18- and 24-months to evaluate long-term clinical outcomes. No study treatment will be provided. Patients will be treated per standard of care as determined by the Investigator and will document topical ophthalmic medications currently being administered at time of study participation.
This is a long-term extension (LTE) follow up study where recruitment of subjects will continue as the parent study (AV-101-002) progresses from Phase 2b to Phase 3. Subjects who were on placebo in Phase 2b and the Intermediate Part of the study who enroll in the LTE study will be re-randomized to one of the 3 active AV-101 doses until such time as the optimal dose has been selected.
This is a phase I trial to see whether patients are able to adhere to a modified, high fat/low carbohydrate diet (the sHFLC + KetoPhyt Diet) with a supplement named KetoPhyt that includes ketones and anti-inflammatory properties.
The classic ketogenic diet (KD) is difficult for patients to adhere to due to its stringent nature. A modified KD has been developed that mimics the glucose lowering, ketone raising effects and the anti-cancer outcomes of the KD.
The TRIOMPHE study is designed to further evaluate the safety and efficacy of the NEXUS™ Aortic Arch Stent Graft System for the endovascular treatment of thoracic aortic lesions involving the aortic arch including chronic dissections, aneurysms, penetrating aortic ulcers and intramural hematoma.
The purpose of this study is to learn if asundexian is safe for the participants, how it affects the body, and to look at how well it works to prevent future ischemic strokes in participants who already had had an acute non-cardioembolic ischemic stroke or high-risk TIA.
The aim of this study is to investigate the use of benralizumab in patients with eosinophilic CRSwNP, and comorbid asthma, whose severity is consistent with a need for surgery despite ongoing treatment with intranasal corticosteroids and a history of treatment with systemic corticosteroids or prior surgery for CRSwNP. The effect of benralizumab 30 mg on nasal polyps will be assessed on top of standard of care therapy with INCS over a 56-week treatment period.
This is a research study being conducted in patients who tested positive for COVID-19 in the past 10 days and are admitted to the hospital. The study is being conducted to assess the safety of an experimental drug called Reparixin. This is provided as tablets along with standard treatment to limit progression of Covid-19 disease. This is a randomized, (which means just like tossing a coin, you will be randomly assigned to receive the study drug or the standard treatment) double-blind trial (which means neither you nor the study team will know which group you are assigned to).
Men with severe symptoms of bladder outlet obstruction often have associated bladder fibrosis leading to diminished bladder contractility. Planning to perform a pilot study using 10 urine samples from controls without urinary symptoms and from 10 men with severe urinary symptoms as noted on the International Prostate Symptom Score (IPSS) questionnaire. Assays will determine levels of collagen within the urine samples from both groups.
